Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boundless BioBOLD -0.60%14 Equity-to-Asset is 0.61 as of Mar. 2026, which is 2% below its 10-year median of 0.62. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Boundless Bio ranks worse than 58.05% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Boundless Bio's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $86.38 Mil. Boundless Bio's Total Assets for the quarter that ended in Mar. 2026 was $140.97 Mil.
The historical rank and industry rank for Boundless Bio's Equity-to-Asset or its related term are showing as below:
BOLD'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.21 Med: 0.62 Max: 0.95
Current: 0.61
During the past 5 years, the highest Equity to Asset Ratio of Boundless Bio was 0.95. The lowest was -1.21. And the median was 0.62.
BOLD's Equity-to-Asset is ranked worse than 58.05% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs BOLD: 0.61
Boundless Bio (NAS:BOLD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Boundless Bio Equity-to-Asset Related Terms
Boundless Bio Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Boundless Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOLD vs XLO, CNTX, INKT: Equity-to-Asset Comparison
For the Biotechnology subindustry, Boundless Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boundless Bio Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Boundless Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Boundless Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Boundless Bio's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boundless Bio (BOLD) has a Equity-to-Asset of 0.61 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Boundless Bio and its competitors. This is near median its historical median of 0.62. According to the industry distribution chart, Boundless Bio ranks #822 out of 1416 companies in the Biotechnology industry, placing it in the top 58.1%.
Is Boundless Bio's Equity-to-Asset too high?
Boundless Bio's current Equity-to-Asset of 0.61 is near median its 10-year median of 0.62. The Biotechnology industry median Equity-to-Asset is 0.68. Boundless Bio's value of 0.61 is 10.3% below this industry median. Based on the distribution chart, Boundless Bio ranks #822 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Equity-to-Asset compare to XLO and CNTX?
According to the Biotechnology industry distribution chart, Boundless Bio ranks #822 out of 1416 companies for Equity-to-Asset. This places Boundless Bio in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Boundless Bio's value of 0.61 is 10.3% below this benchmark. While the company's 10-year median is 0.62 vs. the industry median of 0.68, Boundless Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boundless Bio's current Equity-to-Asset of 0.61 is 10.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Boundless Bio and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boundless Bio's current Equity-to-Asset is 0.61, which is near median its own 10-year median of 0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Equity-to-Asset of 0.61. The current Equity-to-Asset is 0.61, which is near median its 10-year median of 0.62 and 10.3% below the Biotechnology industry median of 0.68. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Equity-to-Asset is 0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score
Get the complete analysis for BOLD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLD has been successfully added to your 
